Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.95 -	0.02 97.86%	0.56 2,655.12%	5.33 848.80%	3.49 34.51%	2.35 32.57%
company equity multiplier	-0.03 -	-0.02 48.76%	-0.38 2,041.89%	1.05 375.47%	1.14 9.46%	1.15 0.12%
days of inventory outstanding
days of payables outstanding						1.08K -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.02 -	1.35 31.53%	1.03 23.24%	0.98 5.01%	0.97 1.38%	0.92 4.96%
effective tax rate	-0.02 -	-0.13 487.44%	-0.03 80.46%	-0.02 30.81%	-0.00 75.25%
enterprise value multiple	-1.35 -	-20.11 1,394.61%	-30.19 50.13%	-4.33 85.65%	-0.72 83.45%	-0.34 52.07%
fixed asset turnover
free cash flow per share	-15.10 -	-0.70 95.36%	-0.64 8.63%	-1.17 82.10%	-1.28 10.00%	-1.15 10.10%
gross profit margin
interest coverage	-38.96 -	-5.51 85.85%	-11.52 108.93%	-55.94 385.78%	-229.17 309.65%	-257.39 12.31%
inventory turnover
long term debt to capitalization	-0.08 -		-0.01 -	0.01 211.32%	0.05 377.97%	0.05 1.66%
net income per ebt	1 -	1.13 13.47%	1.03 9.55%	1.02 0.79%	1.00 1.35%	1 0.45%
net profit margin
operating cash flow per share	-15.05 -	-0.70 95.38%	-0.60 13.93%	-1.09 82.30%	-1.27 16.40%	-1.15 9.87%
operating profit margin
payables turnover						0.34 -
pretax profit margin
price fair value	-0.24 -	-3.39 1,300.13%	-9.90 191.94%	1.10 111.08%	0.44 59.67%	0.30 32.62%
receivables turnover
return on assets	-7.05 -	-15.61 121.45%	-0.96 93.83%	-0.24 74.60%	-0.41 68.63%	-0.46 11.20%
return on capital employed	15.67 -	0.61 96.13%	-1.17 293.17%	-0.25 78.44%	-0.46 81.71%	-0.54 17.45%
return on equity	0.24 -	0.28 13.47%	0.37 32.11%	-0.26 169.96%	-0.47 84.58%	-0.53 11.33%
total debt to capitalization	-0.10 -	-0.31 213.38%	-0.01 96.68%	0.02 255.83%	0.07 355.86%	0.09 21.12%

NASDAQ:SNSE

Sensei Biotherapeutics, Inc.

Last Close

1.57

10/05 20:00

Market Cap

20.00M

Beta: −0.20

Volume Today

148.12K

Avg: 84.31K

PE Ratio

−0.55

PFCF: −0.57